Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Gefitinib

ac652036-df79-5fa5-8787-9a54ee409cb9 · FDA Approved · targets EGFR

Gefitinib

MeasuredReference

Gefitinib targets EGFR, ERBB4_HER4, ERBB2_HER2. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

EGFRERBB4_HER4ERBB2_HER2DDR1LYN

Top hallmarks

  • tumor promoting inflammation3.1k
  • evading apoptosis2.6k
  • proliferation2.6k

Top pathways disrupted

  • apical junction6.1k
  • pi3k akt mtor signaling5.7k
  • allograft rejection5.6k

Resistance landscape — Gefitinib

MeasuredReference

10 known oncogenic variants exist on Gefitinib's top targets — see detail for inhibition impact.

Open in new tab